«上一篇/Previous Article|本期目錄/Table of Contents|下一篇/Next Article»

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:

40

期數(shù):

2018年06期

頁碼:

16-18

欄目:

臨床研究

出版日期:

2018-11-29

文章信息/Info

Title:

Expression of programmed death receptor 1 and its ligand in primary lung mucoepidermoid carcinoma and its clinical significance

文章編號:

1002-2600(2018)06-0016-04

作者:

劉加夫 吳聯(lián)平 林清華 陳友軒 林玉瓊 陳新富¹

福建醫(yī)科大學(xué)教學(xué)醫(yī)院 福建省福州肺科醫(yī)院病理科(福州 350008)

Author(s):

LIU Jiafu; WU Lianping;  LIN Qinghua;  CHEN Youxuan;  LIN Yuqiong;  CHEN Xinfu.

Department of Pathology, Fuzhou Pulmonary Hospital, Teaching Hospital of Fujian Medical University, Fuzhou,Fujian 350008, China

關(guān)鍵詞:

肺腫瘤;  黏液表皮樣癌;  程序性死亡受體1配體

Keywords:

lung neoplasms;  mucoepidermoid carcinoma;  programmed death receptor 1 ligand

分類號:

R361⁺.3;R734.2

文獻(xiàn)標(biāo)志碼:

B

摘要:

目的 探討原發(fā)肺黏液表皮樣癌(pulmonary mucoepidermoid carcinoma,PMC)中程序性死亡受體1(PD-1)及其配體1(PD-L1)、配體2(PD-L2)表達(dá)的臨床意義。方法 采用免疫組化法檢測41例手術(shù)切除原發(fā)肺PMC組織中PD-1、PD-L1、PD-L2和CD8+T細(xì)胞表達(dá)情況,分析它們之間的相關(guān)性及與臨床病理特征的關(guān)系。結(jié)果 顯微鏡下觀察PMC由表皮樣細(xì)胞、中間型細(xì)胞和黏液細(xì)胞構(gòu)成。免疫標(biāo)志物PD-L1在41例PMC中呈陰性; 所有PMC腫瘤組織中CD8+T細(xì)胞均有不同程度表達(dá),且其表達(dá)陽性數(shù)與腫瘤大小呈負(fù)相關(guān); PD-1+T細(xì)胞在癌組織中15例陰性,26例呈陽性表達(dá); PD-L2均有不同程度表達(dá),其中8例高級別黏液表皮樣癌表現(xiàn)為表皮樣細(xì)胞及中間型細(xì)胞胞膜的中等以上強度陽性表達(dá); 33例低級別黏液表皮樣癌中黏液細(xì)胞為陰性、中間型細(xì)胞及表皮樣細(xì)胞胞膜呈局灶陽性。單因素分析PD-L2高表達(dá)與較短的無復(fù)發(fā)生存期相關(guān),多因素分析顯示PD-L2表達(dá)可能是預(yù)測黏液表皮樣癌復(fù)發(fā)的獨立危險因子之一。本研究發(fā)現(xiàn)PD-L2表達(dá)強度與PMC的組織學(xué)分級呈正相關(guān),高級別PMC中PD-L2陽性細(xì)胞比例和染色強度綜合評分明顯高于低級別PMC。結(jié)論 PD-L2是PMC重要的免疫生物標(biāo)志物,可能會成為預(yù)測黏液表皮樣癌復(fù)發(fā)的關(guān)鍵因子之一,其表達(dá)綜合評分情況有助于黏液表皮樣癌組織學(xué)分級,對預(yù)測臨床預(yù)后有一定的作用。

Abstract:

Objective To investigate the clinical significance of programmed death receptor 1(PD-1)and its ligand 1(PD-L1)and ligand 2(PD-L2)in primary lung mucin epidermoid carcinoma(PMC). Methods The expressions of PD-1, PD-L1, PD-L2 and CD8+ T cells in 41 patients with primary lung PMC were detected by immunohistochemistry. The correlation between them and their relationship with clinicopathological features were analyzed.Results Microscopic observation of PMC consisted of epidermal-like cells, intermediate cells, and mucous cells. The immunological marker PD-L1 was negative in 41 cases of PMC; CD8+ T cells were expressed in different degrees in all PMC tumor tissues, and the positive expression number was negatively correlated with tumor size; PD-1+T cells were negative in 15 cases and positive in 26 cases. PD-L2 was expressed in different degrees. Among them, eight cases of high-grade mucoepidermoid carcinoma showed moderate or higher intensity expression of epidermal-like cells and intermediate cell membrane. In 33 cases of low-grade mucoepidermoid carcinoma, mucus cells were negative, and intermediate cells and epidermal-like cell membranes were focally positive. Univariate analysis of PD-L2 high expression was associated with shorter recurrence-free survival. Multivariate analysis showed that PD-L2 expression may be one of the independent risk factors for predicting recurrence of mucoepidermoid carcinoma. This study found that the intensity of PD-L2 expression was positively correlated with the histological grade of PMC. The proportion of PD-L2 positive cells and the comprehensive score of staining intensity in high-grade PMC was significantly higher than that of low-level PMC.Conclusion PD-L2 is an important immunobiomarker for PMC and may be one of the key factors predicting the recurrence of mucoepidermoid carcinoma. The comprehensive evaluation of its expression is helpful for histological grading of mucoepidermoid carcinoma and which has a certain predictive clinical prognosis.

備注/Memo

備注/Memo:

基金項目:福州市科技計劃項目(2015-S-142-5)

常用功能

更新日期/Last Update: 2018-11-29